Discordant response to chemotherapy: An unusual pattern of fluoro-deoxy-D-glucose uptake in heavily pre-treated lymphoma patients

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 1048-1052

  Alinari, Lapo ^a   Ambrosini, Valentina ^a   Castellucci, Paolo ^a   Tani, Monica ^a   Stefoni, Vittorio ^a   Nanni, Cristina ^a   Farsad, Mohsen ^a   Rubello, Domenico ^b   Franchi, Roberto ^a   Zinzani, Pier ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UO Medicina Nucleare   (Italy)

Author keywords

Lymphoma; PET; Pre treated; Progression regression

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; NONIONIC CONTRAST MEDIUM;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DRUG UPTAKE; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REMISSION INDUCTION; TIME FACTORS;

EID: 33746292429     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600555785     Document Type: Article

References (19)

1. Hong, S and Hahn, J and Lee, J and Bae, S and Youn, M. (2003) 18F-fluorodeoxyglucose positron emission tomography in the staging of malignant lymphoma compared with CT and 67-Ga scan Yonsi Medical Journal, 44, pp. 779-786.
2. Friedberg, J and Chengazi, V. (2003) PET scans in the staging of lymphoma: Current status Oncologist, 8, pp. 438-447.
3. Lavely, W and Delbeke, D and Greer, J and Morgan, D and Byrne, D and Price, R and Hallahan, D. (2003) FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy International Journal of Radiation Oncology, Biology & Physics, 57, pp. 307-315.
4. Elstrom, R and Guan, L and Baker, G and Nakhoda, K and Vergilio, J and Zhuang, H and et al. (2003) Utility of FDG-PET scanning in lymphoma by WHO classification Blood, 101, pp. 3875-3876.
5. Kostakoglu, L and Leonard, J and Kuji, I and Coleman, M and Vallabhajosula, S and Goldsmith, S. (2002) Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma Cancer, 94, pp. 879-888.
6. Blum, R and Seymour, J and Wirth, A and MacManus, M and Hicks, R. (2003) Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma Clinical Lymphoma, 4, pp. 43-49.
7. Najjar, F and Hustinx, R and Jerusalem, G and Fillet, G and Rigo, P. (2001) Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL) Cancer Biotechnology & Radiophysics, 16, pp. 297-304.
8. Hoffman, M and Kletter, K and Becherer, A and Jager, U and Chott, A and Raderer, M. (2003) 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma Oncology, 64, pp. 336-340.
9. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group Journal of Clinical Oncology, 17, pp. 1244-1253.
10. Harris, N and Jaffe, E and Stein, H and Banks, P and Chan, J and Cleary, M and et al. (1994) A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group Blood, 84, pp. 1361-1392.
11. Spaepen, K and Stroobants, S and Dupont, P and Van Steenweghen, S and Thomas, J and Vandenberghe, P and et al. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is 18F FDG-PET a valid alternative to conventional methods? Journal of Clinical Oncology, 19, pp. 414-419.
12. Schaefer, N and Hany, T and Taverna, C and Seifert, B and Stumpe, K and von Schulthess, G and Goerres, G. (2004) Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging-Do we need contrast enhanced CT? Radiology, 232, pp. 823-829.
13. Zinzani, P and Fanti, S and Battista, G and Tani, M and Castellucci, P and Stefoni, V and et al. (2004) Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients British Journal of Cancer, 91, pp. 850-854.
14. Spaepen, K and Stroobants, S and Dupont, P and Vandenberghe, P and Thomas, J and de Groot, T and et al. (2002) Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Annals of Oncology, 13, pp. 1356-1363.
15. Hutchings, M and Mikhaeel, N and Fields, P and Nunan, T and Timothy, A. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma Annals of Oncology, 16, pp. 1160-1168.
16. Schiepers, C and Filmont, J and Czerin, J. (2003) PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma European Journal of Nuclear Medicine & Molecular Imaging, 30, pp. 82-88.
17. Spaepen, K and Stroobants, S and Dupont, P and Thomas, J and Vandenberghe, P and Balzarini, J and et al. (2001) Can positron emission tomography with 18Ffluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? British Journal of Haematology, 115, pp. 272-278.
18. Mikhaeel, N and Timothy, A and O'Doherty, M and Hain, S and Maisey, M. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT Leukemia & Lymphoma, 39, pp. 543-553.
19. Kostakoglu, L and Coleman, M and Leonard, J and Kuji, I and Zoe, H and Goldsmith, S. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease Journal of Nuclear Medicine, 43, pp. 1018-1027.